Bradley & Co Private Wealth Management’s 10x Genomics TXG Stock Holding History

Bradley & Co Private Wealth Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-304	Closed	-$3.55K	–	227
2025 Q3	$3.55K	Hold	304	–	–	﹤0.01%	167
2025 Q2	$3.52K	Hold	304	–	–	﹤0.01%	159
2025 Q1	$2.65K	Hold	304	–	–	﹤0.01%	158
2024 Q4	$4.37K	Buy	+304	New	+$4.8K	﹤0.01%	145
2024 Q2	$5.91K	Hold	304	–	–	﹤0.01%	129
2024 Q1	$11.4K	Hold	304	–	–	0.01%	118
2023 Q4	$17K	Hold	304	–	–	0.02%	106
2023 Q3	$12.5K	Hold	304	–	–	0.01%	107
2023 Q2	$17K	Hold	304	–	–	0.02%	104
2023 Q1	$17K	Hold	304	–	–	0.02%	106
2022 Q4	$11.1K	Hold	304	–	–	0.01%	114
2022 Q3	$9K	Buy	+304	New	+$11.6K	0.01%	130

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bradley & Co Private Wealth Management's TXG Position: Q4 2025 in Review

Bradley & Co Private Wealth Management sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 304 shares — an estimated $3.55K sold.

Bradley & Co Private Wealth Management first reported a position in TXG in Q3 2022 and held it in 12 quarters. The position peaked at $17K in Q4 2023. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

Bradley & Co Private Wealth Management reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
Bradley & Co Private Wealth Management sold 304 10x Genomics shares in Q4 2025, an estimated $3.55K.
Bradley & Co Private Wealth Management first reported a position in 10x Genomics in Q3 2022 and held it in 12 quarters.
Bradley & Co Private Wealth Management's 10x Genomics position peaked at $17K in Q4 2023.
322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Bradley & Co Private Wealth Management's 13F filing for Q4 2025, filed 11 Feb 2026.